Eisai Co., Ltd. (ESALF)
| Market Cap | 8.16B |
| Revenue (ttm) | 5.04B |
| Net Income (ttm) | 373.95M |
| Shares Out | n/a |
| EPS (ttm) | 1.31 |
| PE Ratio | 21.83 |
| Forward PE | n/a |
| Dividend | 0.55 (1.81%) |
| Ex-Dividend Date | Sep 27, 2024 |
| Volume | 200 |
| Average Volume | 1,745 |
| Open | 28.86 |
| Previous Close | 30.50 |
| Day's Range | 28.86 - 28.86 |
| 52-Week Range | 24.86 - 45.46 |
| Beta | -0.14 |
| RSI | 46.48 |
| Earnings Date | May 15, 2025 |
About Eisai
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a... [Read more]
Full Company ProfileFinancial Performance
In 2023, Eisai's revenue was 741.75 billion, a decrease of -0.36% compared to the previous year's 744.40 billion. Earnings were 42.41 billion, a decrease of -23.50%.
Financial numbers in JPY Financial StatementsNews
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight
New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight LEQEMBI (lecanemab) has significant market p...
EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug
European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's Alzheimer's drug Leqembi, after it recommended its approval in November.
Eisai: Will Have No Problem Hitting Leqembi Forecasts
Q3 2025 Eisai Co Ltd Earnings Presentation Transcript
Q3 2025 Eisai Co Ltd Earnings Presentation Transcript
Eisai projects 42.5B yen global revenue for LEQEMBI in FY2024 amid pathway expansion
Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript
Eisai GAAP EPS of ¥160.14, revenue of ¥601.16B; reaffirms FY outlook
Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's Alzheimer's drug Leqembi, the agency said on Friday.
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
STOCKHOLM , Jan. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM : BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supp...
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment wi...
Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study
On Friday, Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESAIY) (OTC: ESALF) announced results from the Phase 3 LEAP-015 trial of Keytruda (pembrolizumab) plus Lenvima (lenvatinib), in combinat...
Merck, Eisai post mixed Phase 3 data for Keytruda/ Lenvima in GIT cancer
Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen in GIT cancer. Read more here.
Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve overall survival in patients with a type of esophageal cancer in a late-stage tri...
Biogen partner Eisai reportedly sees FY25 launch for home version of Alzheimer’s drug
Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
TOKYO--(BUSINESS WIRE)-- #IVD--Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Chairman, President and...
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
TOKYO, Dec 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval for "URECE(R)" (generic name: dotinurad) from the National Medical Products Administration in China...
Biogen Inc (BIIB) and Eisai's Alzheimer's Drug LEQEMBI Approved in Mexico
Biogen Inc (BIIB) and Eisai's Alzheimer's Drug LEQEMBI Approved in Mexico
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Needham downgraded Biogen Inc (NASDAQ: BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug Leqembi’s (lecanemab) sales growth is expected to stay gradual without a sh...
Eisai wins orphan drug status for Lenvima for esophageal cancer
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachuset...
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an...
Biogen gains as Eisai wins EU nod for Alzheimer’s drug
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatm...